Vergani, Barbara published the artcileNovel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation, Synthetic Route of 2251-79-8, the publication is Journal of Medicinal Chemistry (2019), 62(23), 10711-10739, database is CAplus and MEDLINE.
Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform whose expression and functional alterations were correlated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and cancer. It is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on non-histone substrates such as tubulin, heat shock protein (HSP)90, Foxp3 and cortactin, to name a few. Selective inhibition of HDAC6 does not show cytotoxic effects in healthy cells, normally associated with the inhibition of Class I HDAC isoforms. Here the authors describe the design and synthesis of a new class of potent and selective HDAC6 inhibitors that bear a pentaheterocyclic central core. These compounds show a remarkably low toxicity both in vitro and in vivo and are able to increase the function of regulatory T cells (Tregs) at well tolerated concentrations, suggesting a potential clin. use for the treatment of degenerative, auto-immune diseases and organ transplantation.
Journal of Medicinal Chemistry published new progress about 2251-79-8. 2251-79-8 belongs to isoxazole, auxiliary class Trifluoromethyl,Fluoride,Benzene, name is 5-(4-(Trifluoromethyl)phenyl)-1H-tetrazole, and the molecular formula is C8H5F3O2S, Synthetic Route of 2251-79-8.
Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem